Physician profile
Anne Ibach
NPI 1023012309
$1,753.36
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,057 · 2020: $274 · 2021: $179 · 2022: $243.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $245.26 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $183.60 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $152.18 | 2019-2022 | |
| Glaxosmithkline, LLC. | $148.99 | 2019-2020 | |
| Pfizer INC. | $125.20 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $117.05 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $113.25 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.61 | 2019 | |
| Astellas Pharma US INC | $53.56 | 2019-2022 | |
| Amgen INC. | $52.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $50.58 | 2019-2021 | |
| Insulet Corporation | $47.04 | 2022 | |
| Eisai INC. | $42.95 | 2020-2022 | |
| Lilly USA, LLC | $42.12 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $41.75 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $31.25 | 2019-2020 | |
| Abbvie INC. | $29.46 | 2021 | |
| Amarin Pharma, INC. | $29.13 | 2019-2020 | |
| Mylan Specialty L.P. | $25.55 | 2021-2022 | |
| Corcept Therapeutics | $20.12 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.38 | 2021 | |
| Horizon Therapeutics Plc | $17.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.39 | 2022 | |
| Sanofi Pasteur INC. | $14.73 | 2019 | |
| Boston Scientific Corporation | $14.64 | 2019 | |
| Acadia Pharmaceuticals INC | $14.29 | 2020 | |
| Medtronic, INC. | $14.12 | 2022 | |
| Hikma Pharmaceuticals USA | $12.65 | 2022 | |
| Therapeuticsmd, INC. | $12.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Ibach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.